371 related articles for article (PubMed ID: 34826977)
1. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
[TBL] [Abstract][Full Text] [Related]
2. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
Ozen S; Ozer MA; Akdemir MO
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1173-1177. PubMed ID: 28299439
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
[TBL] [Abstract][Full Text] [Related]
4. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
Messmer EM; von Lindenfels V; Garbe A; Kampik A
Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain.
Zhao L; Chen J; Duan H; Yang T; Ma B; Zhou Y; Bian L; Cai X; Qi H
BMC Ophthalmol; 2024 Jan; 24(1):28. PubMed ID: 38247010
[TBL] [Abstract][Full Text] [Related]
6. Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease.
Park JY; Kim BG; Kim JS; Hwang JH
Transl Vis Sci Technol; 2018 Sep; 7(5):31. PubMed ID: 30386683
[TBL] [Abstract][Full Text] [Related]
7. Is gabapentin effective in dry eye disease and neuropathic ocular pain?
Ongun N; Ongun GT
Acta Neurol Belg; 2021 Apr; 121(2):397-401. PubMed ID: 31134508
[TBL] [Abstract][Full Text] [Related]
8. A prospective study to assess the role of vitamin D individually and in combination with cyclosporine in the treatment of dry eye in patients with deficient serum 25(OH)D levels.
Watts P; Sahai A; Kumar PR; Shamshad MA; Trivedi GK; Tyagi L
Indian J Ophthalmol; 2020 Jun; 68(6):1020-1026. PubMed ID: 32461420
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease].
Liu SW; Zhao YH; Ma J; Shen Z; Hu BH; Peng RM; Hong J
Zhonghua Yan Ke Za Zhi; 2023 Oct; 59(10):805-813. PubMed ID: 37805414
[No Abstract] [Full Text] [Related]
10. An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease.
Tuan HI; Chi SC; Kang YN
Drug Des Devel Ther; 2020; 14():265-274. PubMed ID: 32021110
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
Moawad P; Shamma R; Hassanein D; Ragab G; El Zawahry O
Eur J Ophthalmol; 2022 Jan; 32(1):673-679. PubMed ID: 33530719
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D Enhances the Efficacy of Topical Artificial Tears in Patients With Dry Eye Disease.
Hwang JS; Lee YP; Shin YJ
Cornea; 2019 Mar; 38(3):304-310. PubMed ID: 30531497
[TBL] [Abstract][Full Text] [Related]
13. Impact of Topical Cyclosporine-A or Topical Chloroquine on Post-LASIK Ocular Surface Stability - A Randomized Controlled Trial.
Titiyal JS; Goswami A; Kaur M; Sharma N; Maharana PK; Velpandian T; Pandey RM
Curr Eye Res; 2023 Jun; 48(6):557-563. PubMed ID: 36800492
[TBL] [Abstract][Full Text] [Related]
14. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
Zhang Q; Zhang H; Qin G; Wu Y; Song Y; Yang L; Yu S; He X; Moore JE; Moutari S; Palme C; Xu L; He W; Pazo EE
J Ocul Pharmacol Ther; 2022 Mar; 38(2):133-140. PubMed ID: 35049373
[No Abstract] [Full Text] [Related]
15. New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study.
Fogagnolo P; Favuzza E; Marchina D; Cennamo M; Vignapiano R; Quisisana C; Rossetti L; Mencucci R
Adv Ther; 2020 Apr; 37(4):1664-1674. PubMed ID: 32185729
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of hypotonic 0.18% sodium hyaluronate eye drops in patients with dry eye disease.
Lee HS; Ji YS; Yoon KC
Cornea; 2014 Sep; 33(9):946-51. PubMed ID: 24915018
[TBL] [Abstract][Full Text] [Related]
17. Effects of the preoperative use of artificial tears combined with recombinant bovine basic fibroblast growth factor on cataract patients complicated with dry eyes.
Xiao W; Huang P
Arq Bras Oftalmol; 2022; 87(2):0539. PubMed ID: 36169441
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G
Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.
Wang TJ; Wang IJ; Ho JD; Chou HC; Lin SY; Huang MC
Clin Ther; 2010 Jan; 32(1):44-52. PubMed ID: 20171410
[TBL] [Abstract][Full Text] [Related]
20. Assessing clinical and molecular outcomes of prophylactic thermal pulsation therapy on ocular surface health following refractive surgery.
Shetty R; Khamar P; Nair AP; Pandian PR; Vaidya TA; Trivedi D; Sethu S; Roy S; Mahajan S; Shirodkar S
Indian J Ophthalmol; 2023 Apr; 71(4):1508-1516. PubMed ID: 37026292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
